Cyteir Therapeutics, Inc. (CYT)
| Market Cap | 546.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 2.34M |
| EPS (ttm) | -14.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,010 |
| Open | 15.54 |
| Previous Close | 15.63 |
| Day's Range | 15.28 - 16.60 |
| 52-Week Range | 14.00 - 23.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 31.50 (+104.0%) |
| Est. Earnings Date | Nov 8, 2021 |
About CYT
Cyteir Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing the next-generation of precision oncology medicines that inhibit deoxyribonucleic acid, or DNA, damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Synthetic lethality represents a clinically validated approach to drug development and arises when there is a deficiency in either of two conditions that are tolerable alone in cells but lethal together. Our lead program, CYT-0851, is in a phase 1...
Financial Performance
Financial StatementsNews
Cyteir Therapeutics Selected to Join Russell 2000® Index
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was...
Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, an...
Cyteir Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...
Cyteir Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, an...
Cyteir Therapeutics Announces Closing of Initial Public Offering
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...
Cyteir Therapeutics Announces Pricing of Initial Public Offering
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...
Cyteir Therapeutics IPO Registration Document (S-1)
Cyteir Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.